We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+1.54%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$79.7M
AUM Growth
-$662M
Cap. Flow
-$660M
Cap. Flow %
-828.28%
Top 10 Hldgs %
21.47%
Holding
303
New
144
Increased
52
Reduced
48
Closed
59

Top Buys

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$1.36M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$1.1M
3
UPW icon
ProShares Ultra Utilities
UPW
+$905K
4
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$786K
5
PBYI icon
Puma Biotechnology
PBYI
+$617K

Top Sells

Rank Stock Value
1
ETP
Energy Transfer Partners, L.P.
ETP
+$93.5M
2
WPZ
Williams Partners L.P.
WPZ
+$65M
3
BPL
Buckeye Partners, L.P.
BPL
+$48.9M
4
ET icon
Energy Transfer Partners
ET
+$45.2M
5
EPD icon
Enterprise Products Partners
EPD
+$40.2M

Sector Composition

Rank Sector Weight
1 Healthcare 70.8%
2 Financials 1.05%
3 Consumer Discretionary 0.59%
4 Technology 0.58%
5 Consumer Staples 0.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYNB
51
Kyntra Bio
KYNB
$28.5M
$405K 0.51%
342
-109
-24% -$137K
MDGL icon
52
Madrigal Pharmaceuticals
MDGL
$12.6B
$402K 0.5%
+4,382
New +$250K
ESPR
53
DELISTED
Esperion Therapeutics
ESPR
$399K 0.5%
6,057
-3,193
-35% -$172K
MYOK
54
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$398K 0.5%
9,447
-1,715
-15% -$66.1K
RETA
55
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$394K 0.49%
13,917
+992
+8% +$27.7K
FOLD
56
DELISTED
Amicus Therapeutics
FOLD
$392K 0.49%
27,241
-10,982
-29% -$151K
KURA icon
57
Kura Oncology
KURA
$922M
$392K 0.49%
+25,648
New +$378K
VYGR icon
58
Voyager Therapeutics
VYGR
$187M
$392K 0.49%
+23,586
New +$404K
CBAY
59
DELISTED
Cymabay Therapeutics
CBAY
$391K 0.49%
+42,485
New +$363K
AIMT
60
DELISTED
Aimmune Therapeutics
AIMT
$391K 0.49%
10,336
-7,562
-42% -$244K
QURE icon
61
uniQure
QURE
$2.68B
$389K 0.49%
+19,842
New +$302K
RIGL icon
62
Rigel Pharmaceuticals
RIGL
$680M
$383K 0.48%
9,873
-2,766
-22% -$105K
AVXS
63
DELISTED
AveXis, Inc. Common Stock
AVXS
$383K 0.48%
3,464
-1,172
-25% -$118K
ACGN
64
DELISTED
Aceragen Inc
ACGN
$381K 0.48%
+1,327
New +$379K
FPRX
65
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$381K 0.48%
17,371
+6,405
+58% +$206K
AGIO icon
66
Agios Pharmaceuticals
AGIO
$2.16B
$379K 0.48%
6,624
+189
+3% +$11.9K
TTPH
67
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$376K 0.47%
2,982
+732
+33% +$93.7K
STML
68
DELISTED
Stemline Therapeutics, Inc.
STML
$374K 0.47%
+23,958
New +$320K
BOLD
69
DELISTED
Audentes Therapeutics, Inc
BOLD
$372K 0.47%
+11,898
New +$327K
LOXO
70
DELISTED
Loxo Oncology, Inc
LOXO
$372K 0.47%
4,424
+11
+0.2% +$917
GBT
71
DELISTED
Global Blood Therapeutics, Inc.
GBT
$370K 0.46%
9,390
-2,455
-21% -$91.7K
RARE icon
72
Ultragenyx Pharmaceutical
RARE
$2.65B
$366K 0.46%
7,893
+2,550
+48% +$125K
ONC
73
BeOne Medicines Ltd
ONC
$33.8B
$365K 0.46%
3,733
-4,380
-54% -$401K
PTCT icon
74
PTC Therapeutics
PTCT
$6.37B
$363K 0.46%
21,752
+2,140
+11% +$36.2K
MRTX
75
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$361K 0.45%
+19,786
New +$307K
1 2
3
4 5

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q4 2017 Portfolio in Review

As of Q4 2017, Virtus ETF Advisers held 303 positions worth $79.7M, down 89% from $742M the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Virtus ETF Advisers withdrew a net $660M in Q4 2017, closing 59 positions and reducing 48 holdings. Its most notable exit was Energy Transfer Partners, L.P., an estimated $93.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 7.9% a quarter earlier, followed by Financials and Consumer Discretionary.

Against the trend, Virtus ETF Advisers opened a new position in iShares MSCI India ETF worth $427K.

  • Virtus ETF Advisers's largest Q4 2017 buy was iShares MSCI India ETF: 11,844 shares worth $427K.
  • Virtus ETF Advisers added most to iShares 20+ Year Treasury Bond ETF in Q4 2017, an estimated $1.36M increase.
  • Virtus ETF Advisers's biggest Q4 2017 reduction was Nektar Therapeutics, cutting an estimated $1.55M.
  • Virtus ETF Advisers fully exited Energy Transfer Partners, L.P. in Q4 2017, selling an estimated $93.5M.
  • Virtus ETF Advisers's ten largest holdings make up 21% of its $79.7M portfolio in Q4 2017.
  • Virtus ETF Advisers opened 144 new positions and closed 59 in Q4 2017.
  • Virtus ETF Advisers's portfolio value fell 89% quarter-over-quarter to $79.7M.

Based on Virtus ETF Advisers's 13F filing for Q4 2017, filed 14 Feb 2018.